Tirzepatide in Pakistan: a patient guide

Tirzepatide activates two receptors involved in appetite and glucose regulation: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual action distinguishes it from medicines such as semaglutide, which activates the GLP-1 receptor.

The ingredient has been studied in type 2 diabetes and long-term weight management. The approved use, dose, device and patient population belong to the exact branded product and country-specific product information. International studies can explain the molecule, but they do not establish the regulatory status or clinical performance of a different product in Pakistan.

Tirzepatide is the active ingredient. Mounjaro® and Zepbound® are separate Eli Lilly brands with their own prescribing information, indications and product-specific evidence. TYZEPA is another separate brand whose package presentation identifies tirzepatide as the active ingredient.

The names should not be used as if they describe one identical medicine. A shared stated ingredient is relevant, but it does not establish identical:

• formulation, concentration or excipients;
• pen, syringe or vial design and dose-delivery accuracy;
• manufacturing and sterility controls;
• stability and storage limits;
• regulatory status;
• clinical effectiveness or side-effect frequency; or
• interchangeability.

For a detailed comparison, read Mounjaro and TYZEPA in Pakistan: what “alternative” really means.

Uses depend on the exact product and the locally applicable prescribing information. Current United States information provides useful context:

• Mounjaro prescribing information describes tirzepatide for improving glycaemic control in eligible people with type 2 diabetes.
• Zepbound prescribing information describes tirzepatide for chronic weight management in eligible adults, alongside reduced-calorie nutrition and increased physical activity, and includes another specified indication for certain adults with obesity.

These examples do not establish that every tirzepatide product has the same approved uses in Pakistan. They also do not mean that tirzepatide is appropriate for every person with diabetes, overweight or obesity.

A qualified clinician should consider the reason for treatment, medical history, current medicines, pregnancy plans, contraindications, side-effect risk, ability to follow up and the exact product being supplied.

Clinical trials show that tirzepatide can produce substantial average weight reduction in selected trial populations. In the 72-week SURMOUNT-5 study, tirzepatide produced a greater average reduction in body weight than semaglutide among adults with obesity, or overweight plus a weight-related complication, who did not have type 2 diabetes.

That result describes averages for the studied products, doses and participants. It does not promise an individual result, prove that tirzepatide is best for every patient, or establish the effectiveness of every product labelled tirzepatide.

Read the full evidence summary in Tirzepatide vs semaglutide: what the evidence shows.

Use the exact product and supply chain as the starting point. Before use, ask a qualified prescriber or pharmacist to help verify:

1. The clinical reason for treatment. Confirm the diagnosis or treatment goal and whether tirzepatide is suitable for you.
2. The exact product. Match the brand, active ingredient, strength, concentration, dosage form and device to the prescription and supplied leaflet.
3. The seller. Use a licensed pharmacy or outlet with a traceable physical location and a qualified pharmacist.
4. The documents. Ask for a dated invoice, manufacturer and supplier details, batch or lot number, expiry date, patient leaflet and the current evidence supporting local authorization or supply.
5. The package. Check that seals are intact and that names, strengths, batch details and dates agree across the carton, immediate container, leaflet and invoice.
6. The storage history. Ask how the product was transported and stored and whether the required temperature range was monitored.
7. The follow-up plan. Know when progress, side effects, blood glucose and other relevant measures will be reviewed.

DRAP describes its online registered-product index as provisional, so unresolved discrepancies should be discussed with DRAP or a qualified pharmacist. A professional-looking package, foreign registration, invoice, security code or customs sticker does not by itself establish every aspect of authenticity, authorization or storage integrity.

Use the tirzepatide authenticity and storage checklist for Pakistan before accepting a product.

Originator tirzepatide information lists nausea, diarrhoea, reduced appetite, vomiting, constipation, indigestion and abdominal pain among commonly reported adverse effects. Important warnings and precautions include pancreatitis, serious allergic reactions, severe gastrointestinal problems, dehydration-related kidney injury, gallbladder disease, diabetic retinopathy complications, hypoglycaemia when used with insulin or a sulfonylurea, and aspiration risk during general anaesthesia or deep sedation.

Originator labelling also carries a warning about thyroid C-cell tumours observed in rats. The relevance to humans is unknown. The Mounjaro and Zepbound labels list a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 and a previous serious hypersensitivity reaction among contraindications.

This is originator-product context. It does not establish TYZEPA-specific side-effect rates or replace the leaflet supplied with the exact product. Review all medicines, medical conditions, pregnancy or breastfeeding, contraception and planned procedures with the prescriber.

Seek urgent medical help for severe or continuing abdominal pain, facial or throat swelling, trouble breathing or swallowing, fainting, severe dehydration, or severe low-blood-sugar symptoms.

Read Tirzepatide side effects and safety: a guide for patients in Pakistan for a fuller explanation.

Obesity, type 2 diabetes, prediabetes, insulin resistance, fatty liver disease and polycystic ovary syndrome can overlap, but the evidence and approved use of a medicine are not identical across these conditions.

Weight management may improve several metabolic risk factors. Research has also examined tirzepatide in selected populations with prediabetes, insulin resistance and metabolic dysfunction-associated steatohepatitis. This does not make those conditions interchangeable or establish a separate indication for every branded product. PCOS-specific reproductive benefits remain under study.

For a broader overview, read Obesity and metabolic health in Pakistan.

• What condition are we treating, and what outcome are we monitoring?
• Why is tirzepatide being considered for me?
• What is the exact brand, strength, concentration and device?
• Which prescribing information applies to this product?
• What evidence and authorization apply to this exact package?
• Who manufactured, supplied and dispensed it?
• How was its storage temperature monitored?
• Which side effects are most relevant to my health and medicines?
• When will treatment be reviewed, adjusted or stopped?
• What should I do before surgery, endoscopy or deep sedation?